Under the best conditions, Thai FDA drug registration runs approximately 12 months. A missed classification, a dossier returned for reformatting, or an improperly structured local holder arrangement can add a full cycle to that. The manufacturers who reach approval on first submission build the regulatory structure before they file.
Thai FDA's official review target is 120 business days for a generic product once a complete dossier is accepted. For a foreign manufacturer, the end-to-end timeline from initial planning to an approved marketing authorization typically runs 12 months or more: local holder setup, import for registration, and dossier preparation all precede the FDA clock. A dossier that reaches the review stage with deficiencies does not get corrected in place: it gets returned. Each return adds months to the total. New drugs run longer at every stage.
The most expensive errors are structural, not technical. Appointing a local holder that does not hold the right establishment license, importing samples under the wrong permit category, submitting a dossier in a format Thai FDA will not accept: these are problems that no amount of technical quality in the underlying data can fix. They require rebuilding the regulatory structure while the clock runs.
The commercial cost is market exclusivity lost to a faster-moving competitor. The operational cost is the regulatory budget spent on a cycle that does not result in approval.
Thai FDA drug registration follows a defined sequence. Each stage has its own requirements, and a deficiency at any point delays the stages that follow. Timelines below are stated as approximate ranges and should be confirmed with Thai FDA or a qualified local specialist before reliance.
Determine the drug control category under the Thai Drug Act (B.E. 2510, 1967) and the registration category before any other decision. Classification governs the data package, the filing form, and the timeline. An error at this stage propagates through every subsequent step.
Thai law requires a licensed Thai entity to hold the marketing authorization. This entity, the Marketing Authorization Holder (MAH) or Local Authorized Representative (LAR), must hold a valid establishment license from Thai FDA. The foreign manufacturer cannot serve as holder unless it operates a licensed Thai establishment. Selecting the right holder is the first structural decision in any market-entry strategy.
Thai FDA requires a current GMP certificate issued by the competent authority of the country of manufacture. Thailand is a Pharmaceutical Inspection Co-operation Scheme (PIC/S) member; certificates from PIC/S-member authorities carry recognized weight but must be current at submission and throughout the review period. An expired certificate can halt a dossier already in review.
Before formal dossier submission, manufacturers typically need to import small quantities for testing and stability studies conducted in Thailand. This requires an import permit specific to registration purposes, issued per product and per approved quantity, and managed through the local holder.
Thailand uses the ASEAN Common Technical Dossier (ACTD) format. Manufacturers familiar with the ICH CTD will find content requirements broadly aligned, but the structural format differs and Thai-language submissions are required for administrative and quality sections (Parts I and II). Parts III and IV (nonclinical and clinical data) are accepted in English. Thai FDA enforces format compliance at screening: a submission that does not meet ACTD format requirements will not advance to review regardless of data quality.
Thai FDA's official registration target is 120 business days for a generic drug and 220 business days for a new drug, assuming documentation is correct and complete at submission. These figures come from Thai FDA's published FAQ. In practice, timelines extend beyond these targets when Thai FDA issues queries: each query response resets the internal review clock, and queue position at the time of submission is a significant variable.
After approval in principle, Thai FDA requires a sample submission for physical and chemical testing against the approved specifications. Products approved under a Safety Monitoring Program (SMP) condition carry mandatory post-marketing safety reporting obligations and are reviewed at intervals before the SMP designation is lifted.
The marketing authorization is issued per product and per dosage form and strength. Under the 2019 amendment to the Drug Act (B.E. 2562, 2019), all new MAs are valid for 7 years from the date of issuance. Renewal applications must be submitted within the 1-year window before expiration. The authorization covers sale in Thailand; a separate import license is required for each commercial consignment.
Under the Thai Drug Act (B.E. 2510, 1967), all drugs sold in Thailand fall into 4 legal control categories. A separate framework applies to herbal products under the Herbal Product Act (B.E. 2562, 2019). Determining which framework and which category applies is the first analytical step in any registration strategy.
Products requiring the highest level of control due to significant safety risks, potential for dependence, or public health sensitivity. This category includes narcotics, psychotropic substances, and certain high-risk prescription products. Import conditions and storage requirements are the most stringent under the Drug Act.
Prescription-only medicines requiring pharmacist supervision for dispensing. The majority of foreign pharmaceutical products seeking registration in Thailand fall into this category. The designation imposes specific labeling, storage, and distribution requirements.
Drugs that do not meet the criteria for specially controlled or dangerous classification. This is a residual category: Thai FDA formally designates specially controlled drugs, dangerous drugs, and household remedies; products not included in those 3 designations are automatically classified as non-dangerous drugs. These products may be sold open-shelf in licensed premises without a prescribing or dispensing requirement.
Over-the-counter products approved for common self-limiting conditions, sold under the household remedy designation (ยาสามัญประจำบ้าน). The approved product list is maintained by the Ministry of Public Health. Household remedies have a simplified registration pathway, but the approved list is narrow and not easily expanded.
The registration category determines the data package Thai FDA requires, the form code used, and the review timeline. Classification is not optional or provisional: Thai FDA will reject a dossier submitted under the wrong category at screening.
Products containing a new chemical entity, a new biological entity, or a new combination not previously registered in Thailand. Products already approved in Thailand that introduce a new indication, a new dosage form, a new route of administration, or a new strength also file under the new drug category. Biologics and biosimilars are processed in this category with additional characterization and comparability requirements. The data burden is the highest of any category; timelines are correspondingly the longest.
A product that references a comparator first approved by Thai FDA after B.E. 2534 (1991). This cutoff is established by ministerial notification rather than the Drug Act itself and is consistently cited in regulatory practice as the dividing line between the new generic and generic pathways. New generics require a bioequivalence study or an appropriate approved waiver. This is the most common pathway for products from established markets entering Thailand for the first time.
A product referencing an older comparator approved before the new-generic cutoff. Data requirements are abbreviated relative to the new-generic pathway, but bioequivalence standards still apply unless a waiver is justified. Review timelines are generally shorter, though queue position and submission quality remain the most significant variables in actual time-to-approval.
A conditional registration pathway for products approved and in commercial use in a recognized stringent regulatory market but with limited Thai-population safety data. SMP approval is time-limited and carries mandatory post-marketing safety reporting requirements. The SMP designation is reviewed periodically and may be converted to full registration once sufficient local safety evidence is accumulated. SMP is not a shortcut: it is a controlled risk-management mechanism.
Thai FDA requires structures that a foreign manufacturer cannot hold or satisfy directly from outside Thailand. Each requirement below must be in place before the relevant stage of registration can proceed. Addressing any of them late in the process is expensive.
Thai law does not permit a foreign manufacturer to hold a Thai marketing authorization unless it operates a licensed Thai establishment. In practice, foreign manufacturers appoint a Thai-licensed entity as the Marketing Authorization Holder (MAH) or Local Authorized Representative (LAR). This entity bears full legal responsibility for the product on the Thai market: labeling, post-marketing surveillance, variation submissions, and license renewal. The quality of this relationship is one of the strongest predictors of registration success and long-term post-approval stability.
Thai FDA issues these as separate authorizations. An establishment license covers a specific legal entity and its licensed premises; a product license covers a specific product in a specific dosage form and strength. A local holder must hold a valid establishment license before a product license can be issued in its name. Approved variations may require amendment to one or both licenses depending on the nature of the change.
Thai FDA requires a current GMP certificate from the competent authority of the country of manufacture. Thailand is a PIC/S member, and certificates from PIC/S-member authorities are accepted. The certificate must be current at submission and remain current throughout the review period: an expired GMP certificate can halt a dossier already in review. For new drug applications, Thai FDA retains the right to conduct its own manufacturing site inspection.
Physical importation into Thailand requires a separate import permit, issued per product and per approved importation. The importer of record must hold an establishment license that covers importation activity. Foreign manufacturers typically designate their local holder or a licensed import agent as the importer of record. The import license is product-specific and does not persist automatically; it must be managed as part of the ongoing compliance structure.
Thailand uses the ASEAN Common Technical Dossier format, not the ICH CTD format directly. Manufacturers experienced with ICH CTD submissions will find the underlying science requirements largely consistent, but the structural format, section numbering, and language requirements differ. Thai FDA screens for ACTD format compliance before review begins; a non-compliant dossier will not advance to review regardless of data quality.
Certain product types follow pathways that sit outside or alongside the standard Drug Act registration route. Each involves distinct requirements, timelines, and regulatory contacts. The descriptions below are educational; they are not a substitute for product-specific regulatory advice.
Biological products are regulated under the Drug Act but require additional manufacturing characterization, comparability, and stability evidence beyond what is typical for small-molecule drugs. Thai FDA has issued guidance specific to biological registration. Biosimilars require clinical and analytical demonstration of similarity to an approved reference biological. VeroPharma Group advises clients on biological registration pathways; the scope of services in this area is confirmed at engagement.
Vaccines are classified as biological products under the Drug Act. The National Institute of Health (NIH) of Thailand is involved in batch release testing for vaccine products destined for the Thai market. Timelines for vaccine registration are subject to national health prioritization and can be accelerated under declared emergency conditions or public health urgency designations.
Thai FDA can grant a time-limited marketing authorization for products addressing a declared public health emergency or significant unmet medical need. This pathway has been used for vaccines and antivirals during acute outbreak events. Conditional approval carries mandatory post-marketing conditions and typically requires a commitment to pursue full registration within a defined timeframe. It is not an alternative to full registration; it is a controlled interim mechanism.
Products meeting the definition of a herbal product under the Herbal Product Act (B.E. 2562, 2019) are regulated separately from drugs under the Drug Act. They fall under the Thai Traditional and Alternative Medicine division of Thai FDA, with its own registration forms, data requirements, fees, and review process. Foreign manufacturers with botanical, traditional, or natural health products must determine at the outset which framework applies. The classification has material consequences for the data package required, the timeline, and the ongoing compliance obligations.
Most Thai FDA registration delays do not start with a technical deficiency in the dossier. They start earlier, in the communication between a foreign manufacturer and its local holder.
Foreign teams often interpret silence as forward progress. Thai regulatory practice is more nuanced: a query not yet formally issued may still be forming; an acceptance at one stage does not confirm the next stage is clear. When a foreign team misreads this gap, it may commit commercial resources against a timeline that no one in Thailand has actually confirmed.
A second common failure is scope creep in the dossier itself: adding data intended to strengthen the submission that instead surfaces questions Thai FDA had not planned to ask. A well-structured, complete-on-first-submission dossier consistently outperforms a richer one submitted late or with unresolved internal inconsistencies.
Neither of these failures reflects poorly on Thai FDA or on local business practice. They reflect the practical difficulty of managing a regulated process across 2 languages, 2 regulatory traditions, and different working assumptions about what constitutes a confirmed status. An experienced local specialist who communicates clearly and early changes the outcome more than any single piece of dossier work.
All fees below are set by the Thai Ministry of Public Health under the Ministerial Regulation on Drug Fees B.E. 2566 (2023 CE) and the MoPH Notification on Costs Collectable from Applicants B.E. 2568 (2025 CE), in force from 31 December B.E. 2568 and as amended by Notification No. 2, B.E. 2569 (2026 CE). Fees are paid to Thai FDA and are non-refundable on rejection.
| Drug Type | Screening (THB) | Evaluation (THB) | MA Certificate (THB) | Total (THB) |
|---|---|---|---|---|
| New Drug — New Chemical Entity (NCE) | 2,500 | 182,500 | 2,000 | 187,000 |
| New Drug — non-NCE (new indication, form, route, or strength) | 2,500 | 155,000 | 2,000 | 159,500 |
| Biosimilar | 1,000 | 196,500 | 2,000 | 199,500 |
| Human Vaccine | 2,500 | 182,500 | 2,000 | 187,000 |
| Generic Drug — specification or method not matching the official pharmacopoeia | 1,000 | 59,000 | 2,000 | 62,000 |
| Generic Drug — specification and method matching the official pharmacopoeia | 1,000 | 39,000 | 2,000 | 42,000 |
| License | Annual Fee (THB) | Notes |
|---|---|---|
| Drug Import License | 10,500 | Expires 31 December each year; must be renewed annually regardless of MA validity |
| Drug Manufacturing License | 8,500 | Applies to Thailand-based manufacturers; not assessed against overseas manufacturing sites |
| Drug Selling License — Retail | 2,500 | Required for licensed retail dispensing establishments |
| Drug Selling License — Wholesale | 2,000 | Required for licensed wholesale distribution |
Post-approval variation, renewal, inspection, and advertising fees: The complete government fee schedule — including post-approval variation fees by MaV/MiV category, MA renewal costs, GMP and GDP inspection fees, bioequivalence study fees, SMP release, clinical trial authorization, and drug advertising permit fees — is published on the full government fee schedule page.
Drug advertising permit (ฆท. / ฆศ.): Pre-approval is mandatory before any drug advertisement is disseminated. ฆท. covers general and consumer-facing media; ฆศ. covers advertising directed at healthcare professionals. Government costs are charged per application: ฆศ. totals 3,200 THB (200 administrative + 3,000 technical assessment); ฆท. totals 2,200 THB (200 administrative + 2,000 technical assessment). Giveaway or promotional item advertising totals 400 THB (200 + 200). Permits are valid up to 5 years from approval. Confirmed from the MoPH Notification on Costs Collectable from Applicants B.E. 2568, Schedule 1 item 3.1 and Schedule 2 items 7.1–7.4.
Our work is done by senior Thai regulatory professionals, not by coordinators or intermediaries. Every engagement is managed by people who have prepared dossiers, managed Thai FDA correspondence, and structured local holder relationships over many years.
We operate in Thai and in English, in the language and register each situation requires. We do not translate what we think a client wants to hear. When the answer to a question about timeline, classification, or pathway feasibility is no, or not yet, or it depends on a variable you have not resolved, we say that.
Our clients are typically not new to drug registration. They are new to Thailand. Our job is to make the Thai regulatory system legible to a team that already understands what registration means, without adding a layer of opacity in the process.